$1.08 Million in Sales Expected for Mersana Therapeutics Inc (NASDAQ:MRSN) This Quarter

Wall Street analysts expect Mersana Therapeutics Inc (NASDAQ:MRSN) to post sales of $1.08 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Mersana Therapeutics’ earnings, with the highest sales estimate coming in at $1.25 million and the lowest estimate coming in at $1.00 million. Mersana Therapeutics posted sales of $4.19 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 74.2%. The company is scheduled to announce its next earnings report on Tuesday, August 13th.

According to Zacks, analysts expect that Mersana Therapeutics will report full-year sales of $42.98 million for the current financial year, with estimates ranging from $41.04 million to $44.79 million. For the next financial year, analysts anticipate that the company will report sales of $4.83 million, with estimates ranging from $4.00 million to $5.50 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for Mersana Therapeutics.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.73. The company had revenue of $41.04 million during the quarter, compared to the consensus estimate of $30.11 million. Mersana Therapeutics had a negative return on equity of 57.49% and a negative net margin of 61.68%.

MRSN has been the topic of several research analyst reports. Cowen reaffirmed a “buy” rating on shares of Mersana Therapeutics in a research note on Sunday, June 2nd. Zacks Investment Research cut Mersana Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. JPMorgan Chase & Co. cut Mersana Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, March 11th. Finally, Robert W. Baird set a $12.00 target price on Mersana Therapeutics and gave the company a “buy” rating in a research report on Friday, March 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $21.60.

Shares of NASDAQ MRSN traded down $0.09 during mid-day trading on Thursday, reaching $4.10. The company had a trading volume of 114,800 shares, compared to its average volume of 238,246. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.24 and a current ratio of 6.24. Mersana Therapeutics has a one year low of $2.85 and a one year high of $19.60. The firm has a market cap of $199.95 million, a price-to-earnings ratio of -1.47 and a beta of 1.39. The company has a 50-day moving average price of $4.46.

Hedge funds have recently bought and sold shares of the business. NEA Management Company LLC lifted its position in shares of Mersana Therapeutics by 46.0% during the 1st quarter. NEA Management Company LLC now owns 11,894,267 shares of the company’s stock valued at $62,564,000 after buying an additional 3,750,000 shares during the last quarter. Sphera Funds Management LTD. bought a new stake in shares of Mersana Therapeutics in the 1st quarter worth $1,052,000. Vanguard Group Inc. increased its holdings in shares of Mersana Therapeutics by 34.4% in the 3rd quarter. Vanguard Group Inc. now owns 601,101 shares of the company’s stock worth $6,011,000 after purchasing an additional 153,923 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Mersana Therapeutics in the 4th quarter worth $277,000. Finally, Bank of America Corp DE increased its holdings in shares of Mersana Therapeutics by 1,409.6% in the 4th quarter. Bank of America Corp DE now owns 31,807 shares of the company’s stock worth $129,000 after purchasing an additional 29,700 shares in the last quarter. 77.40% of the stock is currently owned by institutional investors and hedge funds.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.

Featured Article: The limitations of an equal weight rating

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.